Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 14, 2005. The report serves as a notification of changes in director interests regarding Ordinary Shares and American Depositary Receipts (ADRs) under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation adjustments for specific directors.
Material Changes
Material changes reported relate to the notional increase in director shareholdings following the dividend paid on January 6, 2005:
- Dr. J.P. Garnier: Interest increased by 1,703.863 ADRs at $44.15 per ADR.
- Dr. T. Yamada: Interest increased by 511.159 ADRs at $44.15 per ADR.
- Mr. J.D. Coombe: Interest increased by 1,036.225 Ordinary Shares at £11.93 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that accrued notional dividends will be paid out proportionally based on the percentage of Performance Share Plan holdings that vest after the relevant three-year measurement period.
Investor Verification Points
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan.
- Confirm the total number of shares outstanding and the impact of these notional increases on director ownership percentages.
- Review the dividend payment details for January 6, 2005, to validate the pricing used for reinvestment ($44.15 for ADRs and £11.93 for Ordinary Shares).